Mindset Pharma: Reformulating First Generation Psychedelic Drugs To Make Them Better
Mindset Pharma (CNSX: MSET)(OTCMKTS: MSSTF) is among the more interesting drug discovery and development companies in the psychedelic space, focused on creating optimized and patentable next-generation psychedelic medicines. In other words, the company is attempting to take first-generation psychedelic compounds and reformulating them to make them better. With many industry leaders attending the Wonderland Psychedelic Conference last week, TDR caught up with Mindset CEO James Lanthier and Chief Scientific Officer Joe Araujo in the harbor.
Mindset Pharma is among the mid-tier psychedelic reformulation companies looking to make a statement with investors. The company specializes in applying innovative medicinal chemistry to create a pipeline of optimized psychedelic medications with improved efficacy and reduced toxicity.
The company’s lead compound, MSP-1014, is a differentiated psilocybin-based from Mindset’s family of patent-pending psychedelic compounds. MSP-1014 was the first drug candidate identified by the company to progress towards human clinical trials for Treatment-Resistant Depression and End-of-Life Cancer Angst after displaying high rates of success through a comprehensive range of specialized preclinical in vitro and in vivo tests.
Mindset Pharma is also diversifying its compound portfolio across a broad spectrum of psychedelic compounds—not limiting itself to psilocybin solely. It currently has 4 final Patent Cooperation Treaty applications and 4 provisional applications filed covering a broad range of novel, next generation drugs inspired by psilocybin, DMT and 5-MeO-DMT—including a novel psilocybin synthesis method. By filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in a 153 countries.
Speaking with TDR Founder Shadd Dales in Miami, CSO Joe Araujo sounded optimistic on proprietary psilocybin compound, MSP-1014:
What we see with (MSP) 1014 is both a stronger response—in terms of 5H2A response—serotonin 2A agonism so we see that in a (HW) model. But we’re also seeing safety improvements. So, psilocybin in high doses reduces body temperature in mice. (MSP) 1014 doesn’t do that. So, we have a really clear understanding where 1014 differentiates from psilocybin, LSD and other drugs.
Click on the embedded link for more of our newest interview with Mindset Pharma CEO James Lanthier, and CSO Joe Araujo, in their own words.